2022 - Research.com Best Scientist Award
His primary areas of study are Internal medicine, Endocrinology, Schizophrenia, Psychiatry and Clozapine. His Internal medicine research is multidisciplinary, relying on both Anesthesia, Pharmacogenetics, Pharmacology and Depression. His Endocrinology research focuses on Serotonin and how it connects with Platelet.
His Schizophrenia study combines topics from a wide range of disciplines, such as Psychosis, Neuroscience, Clinical psychology and Verbal fluency test. Many of his research projects under Psychiatry are closely connected to Suicide prevention with Suicide prevention, tying the diverse disciplines of science together. His research in Clozapine intersects with topics in Extrapyramidal symptoms, Antipsychotic, Atypical antipsychotic, Mechanism of action and Haloperidol.
Herbert Y. Meltzer spends much of his time researching Internal medicine, Endocrinology, Schizophrenia, Psychiatry and Pharmacology. His Endocrinology research incorporates elements of Receptor and Serotonergic. Herbert Y. Meltzer frequently studies issues relating to Psychosis and Schizophrenia.
His work on Psychopathology, Cognition and Schizophrenia as part of general Psychiatry study is frequently linked to Suicide prevention, therefore connecting diverse disciplines of science. His Pharmacology study combines topics in areas such as Haloperidol, Antagonist, Dopamine receptor D2, 5-HT receptor and Phencyclidine. As a part of the same scientific study, Herbert Y. Meltzer usually deals with the Clozapine, concentrating on Atypical antipsychotic and frequently concerns with Melperone.
Schizophrenia, Internal medicine, Antipsychotic, Pharmacology and Clozapine are his primary areas of study. His Schizophrenia research is included under the broader classification of Psychiatry. His Psychiatry research includes elements of Clinical trial and Clinical psychology.
His Internal medicine research incorporates themes from Endocrinology, Olanzapine, Oncology and Single-nucleotide polymorphism. The concepts of his Pharmacology study are interwoven with issues in Phencyclidine, Agonist, Partial agonist and Dopamine receptor D2, Dopamine. Clozapine is frequently linked to Atypical antipsychotic in his study.
The scientist’s investigation covers issues in Pharmacology, Atypical antipsychotic, Schizophrenia, Internal medicine and Antipsychotic. His studies in Pharmacology integrate themes in fields like Agonist, Inverse agonist, Lurasidone, Pimavanserin and Phencyclidine. His Atypical antipsychotic study incorporates themes from Haloperidol, Clozapine, Amisulpride and Dopamine receptor D2.
His Schizophrenia study is concerned with the field of Psychiatry as a whole. His work deals with themes such as Tolerability and Clinical trial, which intersect with Psychiatry. Herbert Y. Meltzer has researched Internal medicine in several fields, including Schizoaffective disorder, Endocrinology and Olanzapine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
John Kane;Gilbert Honigfeld;Jack Singer;Herbert Meltzer.
Archives of General Psychiatry (1988)
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
Grazyna Rajkowska;José J Miguel-Hidalgo;Jinrong Wei;Ginny Dilley.
Biological Psychiatry (1999)
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
H Y Meltzer;S Matsubara;J C Lee.
Journal of Pharmacology and Experimental Therapeutics (1989)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph Patrick McEvoy;Jonathan M. Meyer;Donald C. Goff;Henry A. Nasrallah.
Schizophrenia Research (2005)
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Herbert Y. Meltzer;Larry Alphs;Alan I. Green;A. Carlo Altamura.
Archives of General Psychiatry (2003)
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Herbert Y. Meltzer;Susan R. McGurk.
Schizophrenia Bulletin (1999)
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)
Practice guideline for the treatment of patients with schizophrenia
M. I. Herz;R. P. Liberman;T. H. McGlashan;J. A. Lieberman.
American Journal of Psychiatry (1997)
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis.
American Journal of Psychiatry (2006)
The Dopamine Hypothesis of Schizophrenia: A Review*
Herbert Y. Meltzer;Stephen M. Stahl.
Schizophrenia Bulletin (1976)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: